Evaluation of Safety, Tolerability, and Pharmacokinetics of APC148 in a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Adults

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of APC148 in healthy adults. This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose trial. The clinical relevance of this study lies in its potential to inform future therapeutic strategies for managing **urinary tract infections (UTIs)** and **complicated UTIs (cUTIs)**. Understanding the safety profile and pharmacokinetic properties of APC148 is crucial for determining its suitability for further clinical development in treating these conditions.

The clinical trial focuses on **urinary tract infections (UTIs)**, including complicated UTIs (cUTI). The study population comprises both male and female participants, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Participants were selected without any specific lifestyle considerations such as diet, physical activity, or habits being highlighted. The sponsor has not disclosed detailed inclusion or exclusion criteria for this trial.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** study to evaluate the safety, tolerability, and pharmacokinetics of APC148 in healthy adults. This first-in-human trial will follow a single ascending dose format. The study is focused on the medical condition of **urinary tract infections (UTIs)**, specifically complicated UTIs (cUTI). The trial is categorized as a Phase 1 study, with an estimated recruitment start date of April 1, 2024, and an anticipated end date of March 31, 2025.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The sequence of study visits will include initial dosing, followed by multiple follow-up visits to monitor safety and collect pharmacokinetic data. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather comprehensive data.

The expected length of participant involvement will vary depending on the dosing schedule and follow-up requirements, but it is anticipated to span several weeks. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or non-compliance with study procedures. The trial is structured to ensure rigorous monitoring and adherence to ethical standards, with participant safety as a primary focus throughout the study duration.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be described. The trial documentation does not include any product authorization status or details about the product's pharmaceutical form and substance origin.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of April 1, 2024, and an estimated end date of March 31, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a systematic approach to collect and analyze data, ensuring that the results are scientifically valid and reliable. The study will adhere to rigorous standards typical of clinical trials to evaluate the potential benefits of the investigational product.